Full-Time
Senior Director, Medical Affairs Learning & Development
Dyne Therapeutics
201-500 employees
Develops muscle-disease therapies using FORCE platform
Compensation Overview
$245k - $270k/yr
Waltham, MA, USA
Remote
Travel up to 30% required.
Bachelor's, Master's, PhD, MD
 People & HR (1) |
|---|
Get referred to Dyne Therapeutics
See people who can refer or advise you
- An advanced scientific or healthcare degree is required; PharmD, PhD, MD, DO, DNP, PA, NP, or equivalent is preferred.
- At least 15 years of progressive experience in biopharmaceutical, pharmaceutical, biotechnology, or healthcare organizations is required.
- Significant experience in Medical Affairs, field medical leadership, Medical Education, training, learning and development, or related functions is required.
- Demonstrated success designing, implementing, and measuring Medical Affairs or field medical training programs is required.
- Experience supporting product launches and launch readiness initiatives in a regulated biopharmaceutical environment is required.
- Strong understanding of Medical Affairs functions, including scientific exchange, medical communications, publications, congress strategy, advisory boards, insight generation, and field medical activities is required.
- Experience developing and facilitating scientific, clinical, and disease-state educational content is required.
- Deep understanding of adult learning principles, instructional design, capability building, change management, and learning measurement is required.
- Strong knowledge of regulatory, compliance, and ethical requirements governing Medical Affairs activities is required.
- Demonstrated ability to influence senior leaders, align stakeholders, and build effective cross-functional partnerships in a matrixed environment is required.
- Strong project management and vendor management experience is required.
- Experience using learning management systems, digital learning platforms, training analytics, and learner feedback to improve program effectiveness is required.
- Ability to lead teams, develop talent, and build high-performing organizations is required.
- Ability to travel up to 30% is required.
- Develop and execute Dyne's Medical Affairs training vision, strategy, and multi-year capability roadmap.
- Build scalable training frameworks that support organizational growth, launch readiness, field excellence, and evolving Medical Affairs priorities.
- Partner with Medical Affairs leadership to assess current and future capability needs across Medical Affairs, with a priority on the field medical team.
- Serve as the strategic advisor on adult learning methodologies, scientific education, and field medical capability development.
- Establish governance, standards, and best practices for Medical Affairs learning, certification, and capability development.
- Design and implement programs that strengthen field medical excellence, strategic account engagement, insight generation, and customer interaction capabilities.
- Create assessment and certification approaches that promote consistency, quality, and confidence across Medical Affairs interactions.
- Implement coaching, reinforcement, and development frameworks that support sustained field effectiveness.
- Support Medical Affairs leadership in establishing competency models and career development pathways.
- Leverage field insights and performance observations to inform training priorities and continuous improvement opportunities.
- Lead the design, deployment, and continuous improvement of Medical Affairs curricula across foundational, role-based, launch, and advanced learning needs.
- Develop onboarding programs that enable new Medical Affairs colleagues to build scientific acumen and verbal fluency, understand Dyne's ways of working, and reach role readiness quickly.
- Create and maintain disease-state, clinical, scientific, product, competitive intelligence, and healthcare ecosystem training programs.
- Develop scientific communication, presentation, moderation, and compliant medical exchange training for high-quality external engagement.
- Partner with cross-functional subject matter experts to keep learning content accurate, current, compliant, and aligned with business priorities.
- Ensure training reflects current clinical data, publications, regulatory developments, competitive context, and Medical Affairs priorities.
- Lead Medical Affairs launch training strategy and execution for current and future product launches.
- Develop launch certification programs that define and measure scientific, compliance, and customer-facing readiness standards.
- Build training programs that enhance scientific storytelling, evidence communication, medical education delivery, and healthcare professional engagement.
- Prepare Medical Affairs teams to support advisory boards, congress activities, investigator interactions, publications, and medical education initiatives with scientific credibility and compliance excellence.
- Partner with Medical Affairs leadership to develop advanced learning pathways for high-potential talent and future leaders.
- Ensure Medical Affairs training programs comply with applicable regulatory requirements, company policies, industry standards, and internal compliance expectations.
- Partner with Compliance, Legal, Regulatory Affairs, and Quality Assurance to ensure appropriate governance and documentation of training activities.
- Oversee learning technologies, training systems, vendors, and external educational partners.
- Establish learning metrics, dashboards, and measurement frameworks to evaluate capability growth, learner experience, and business impact.
- Drive continuous improvement through learner feedback, training analytics, competency assessments, and performance outcomes.
- Collaborate with Commercial Training, Learning & Development, Compliance, Medical Affairs, and Clinical Development teams to maximize organizational learning effectiveness.
- Align Medical Affairs capability development with broader organizational priorities, enterprise learning strategies, and launch readiness efforts.
- Support enterprise-wide education and capability initiatives where scientific, medical, or launch expertise is required.
- Foster a culture of continuous learning, development, and scientific excellence across Medical Affairs.
- PharmD, PhD, MD, DO, DNP, PA, NP, or equivalent healthcare or scientific degree.
Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.
Company Size
201-500
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2017
Get referred to Dyne Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Dyne ended June 30, 2026 with $898.5 million cash and July equity proceeds.
- ACHIEVE enrolled 71 participants in June 2026; HARMONIA dosing began July 2026.
- FDA granted Priority Review for z-rostudirsen July 20, 2026, signaling regulatory momentum.
What critics are saying
- Sarepta's Exondys 51 and gene-therapy franchise defend exon-51 patients before January 2027.
- If z-rostudirsen misses approval, Dyne stays pre-revenue and financing resets by 2028.
- June 30, 2026 net loss hit $178.6 million, pressuring execution across three programs.
What makes Dyne Therapeutics unique
- FORCE™ targets muscle delivery, pairing oligonucleotides with tissue-specific uptake, not broad systemic exposure.
- Zeleciment rostudirsen's January 21, 2027 PDUFA is first-in-class commercialization for Dyne.
- Dyne spans DMD, DM1, and FSHD, creating multiple shots on muscle-disease biology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↓ -1%Dyne Therapeutics shares dropped 31% to $16.76 in premarket trading on Tuesday, with no official company announcement explaining the decline. The biotechnology firm is developing treatments for neuromuscular diseases, including z-rostudirsen for Duchenne muscular dystrophy, which has a regulatory decision date of 21 January 2027. The company recently reported a quarterly net loss of $178.6 million, or $1.08 per share, missing consensus estimates of $0.75 per share. The sharp decline stood in contrast to broader market moves, with the S&P 500 down 0.3% and the Nasdaq slipping 0.1% during the same period. No new clinical or regulatory developments were confirmed to explain the trading movement.
Dyne Therapeutics has commenced an underwritten public offering of $300 million of its common stock. The clinical-stage company, which focuses on treatments for genetically driven neuromuscular diseases, also plans to grant underwriters a 30-day option to purchase up to an additional $45 million of shares. Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also serving as joint book-running managers, whilst Jones is acting as lead manager. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on 5 March 2024. The company is currently developing clinical programmes for myotonic dystrophy type 1 and Duchenne muscular dystrophy.
Dyne gets early 2027 decision date for Duchenne therapy, analysts expect 'smooth' review. July 21, 2026 | If approved, Dyne Therapeutics' zeleciment rostudirsen could "capture the majority" of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Therapeutics' exon-skipping therapy Exondys 51, the current standard of care, according to Oppenheimer. The FDA has accepted Dyne Therapeutics' application for its investigational Duchenne muscular dystrophy therapy, setting a target action date of Jan. 21, 2027. "We anticipate a smooth approval," Oppenheimer told investors in a note on Monday, adding that the therapy, dubbed zeleciment rostudirsen (z-rostudirsen) is poised to "capture the majority of market share," given stronger dystrophin benefits and a more convenient dosing profile than the current standard treatment. Outside of symptomatic management through corticosteroids, Sarepta Therapeutics' Exondys 51 is a standard of care regimen for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Dyne, however, could challenge Exondys with z-rostudirsen, which in the Phase 1/2 DELIVER trial outperformed Sarepta's asset, Jefferies said in a Monday note, adding that the early data cut looks "best-in-class." Exondys is dosed weekly, while z-rostudirsen is designed to be given once every four weeks - a "convenient" profile, the firm noted. Given its convenience and efficacy advantages, "z-rostudirsen could command a pricing premium" if approved, Jefferies continued. The analysts added that they expect uptake to be "robust" across three key patient subgroups: those who have yet to undergo Exondys treatment, those who have discontinued Sarepta's therapy and those who are currently receiving it. Dyne is seeking accelerated approval for z-rostudirsen in patients with DMD who are amenable to exon 51 skipping, according to a company release on Monday. Topline data from the registrational cohort of DELIVER, released December 2025, showed a 5.46% increase at six months in concentrations of the dystrophin protein, a key disease marker. Patients also saw improvements in key functional measures, including time-to-rise velocity and the 10-meter walk/run test. Lung function, a major driver of death in DMD, was preserved at six months. Dyne's exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the "best ever" for this treatment class, Stifel analysts said. December 8, 2025 The FDA does not plan on holding an advisory committee meeting for z-rostudirsen, according to Dyne. Jefferies models more than $500 million in peak sales for z-rostudirsen, calling this estimate "conservative." Oppenheimer, on the other hand, did not provide a peak forecast for the z-rostudirsen, only noting that Dyne's therapy could secure a "majority" of the $1.5 billion exon-51 DMD market. In DMD, a rare and progressive neuromuscular disorder, mutations to the dystrophin protein render it dysfunctional or completely absent. Under healthy conditions, dystrophin plays a crucial role in maintaining the structure and function of muscles. Z-rostudirsen works by restoring the expression of near-full-length dystrophin, in turn restoring the function of the protein. A key player in the DMD space is Sarepta, which aside from Exondys owns the gene therapy Elevidys. Last year, two patients died after receiving Elevidys, which ultimately forced the FDA to slap a boxed warning on the product's label and limited its use to ambulatory patients four years and up. Sarepta also owns Amondys 45 and Vyondys 53 - both exon-skipping drugs like Exondys - which in November 2025 failed to elicit significant motor function improvements in the confirmatory Phase 3 ESSENCE study. Sarepta has nevertheless pushed for full approval of these products, with the FDA setting a decision date of Feb. 28, 2027. Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs' failure to improve motor function in a confirmatory trial. July 1, 2026
Dyne Therapeutics announces a $300 million public offering of common stock to support its neuromuscular disease programs.Quiver AI SummaryDyne Therapeutics, Inc. has announced the commencement of an underwritten public offering of $300 million in shares of its common stock, with a potential additional sale of $45 million if underwriters exercise their option. The shares will be sold by Dyne, and the offering is being managed by Morgan Stanley, Je
Dyne Therapeutics completes $230 million public offering of 27.8 million shares to advance neuromuscular disease therapies. |